SREBF1 and fatty liver disease: The inhibition of PARP-1 can activate the PI3K/AKT pathway to down-regulate the expression of the fat synthesis gene SREBP-1c, reduce lipid synthesis and accumulation, and improve fatty liver disease in HFHS diet mice (Wang et al., 2019).